reason report
bottom line deliv oper solid mark
org cc revenue growth y/i ep y/i upsid vs
consensu anoth qtr y/i margin expans upper-end
guidanc plu guidanc rais full-year
org revenue growth ep full-year benefit
diversif evid neuro/spine/trauma out-performance
counter medsurg under-perform vs consensu rest
ortho line mako placement remain strong util
per system rise help drive significantli above-mkt growth
knee similar last qtr expect top-lin
perform prove one best large-cap med-tech
qtr moreov encourag see y/i oper margin expans
mid-teen ep growth margin expans
one miss ingredi stori view
org revenue growth solid consensu
plu clean ep beat anoth y/i op margin
perform revenu y/i organ sell
day adj line consensu report
consensu y/i organ growth -- -we consensu
neuro/spin stood quarter acceler y/i
growth cc org us spine flip posit growth territori
follow multi-qtr stretch neg perform out-performance
neurotech counter under-perform medsurg cc
org elong sell cycl camera impact
endoscopi ortho cc org growth sell day adj line
 gm consensu op-ex
street ebit margin came consensu reflect
y/i expans tax serv margin ep tailwind
qtr ep beat mostli oper driven vs
org rev/ep outlook increas management continu
expect least op margin improv y/i
bump organ revenu growth guidanc -- -in addit
rais -- -now vs ep
guid vs prior reflect flow
oper beat absorb increment
currenc headwind sinc last guidanc updat tailwind vs
prior guid management reiter expect minimum
op margin improv ep rang continu
assum headwind relat dilut entellu acquisit
contempl fx tailwind vs prior
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
compani inform leerink partner llc research
revenu million ep present cash
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
continu take share us knee ortho end-market
appear steadi market improv vs margin
us knee growth y/i sell day adj continu
reflect impress share gain market estim base
result far op grew mako
management character us larg joint market basic stabl
though result op snn tough say
sure mako continu drive knee momentum especi
competit account management note implant growth higher
us hip growth y/i sell day adj management
expect new product launch contribut margin
hope acceler growth market go forward
mako ramp continu anoth qtr solid system
placement vs total
knee upgrad pace ahead schedul instal base
upgrad placement go competit account
acct lower market share roughli
custom base mako management indic total
knee applic drove meaning increment share gain
mako tka perform -- -up util per system
increas y/i management suggest could place robot
mani hospit orthoped practic current
mean consider runway left placement halo effect
like drive perform across entir ortho portfolio
neurotech saw standout perform qtr spine
busi went back posit territori us growth y/i
face continu soft us market management call msd
price pressur core busi off-set continu dd
growth differenti product print cage
qtr encourag unclear when/what take turn
challeng end-market around on-going strength us neurotech
segment y/i org drove combin neurotech/spin divis
strong demand neurovascular product hemorrhag
ischem stroke benefit continu market expans
ischem stroke provid lift market whole believ
neuro capabl sustain momentum
roll new product trauma extrem maintain posit
momentum hsd cc growth
medsurg cc org y/i came expect part
due slower-than-expect endoscopi growth instrument
solid perform driven us growth org endoscopi
cc under-perform qtr vs model us core growth
cite elong camera sale cycl tough y/
comp within medic recoveri progress product
line launch full recoveri expect capit environ
remain stabl accord management though segment perform
forecast org cc growth trend still healthi
model updat decreas revenue y/i org
cc revenue decreas larg due fx headwind
tailwind vs prior new ep
y/i toward high end guidanc project
org cc y/i growth ep
rate share outperform price target remain one
higher qualiti compani large-cap med-tech univers today increasingli
diversifi medic devic compani one believ like drive least mid
high-singl digit top-lin high-singl digit low dd digit bottom-lin growth
compound-annual-growth-rate busi mix continu evolv core reconstruct
implant busi hips/kne total sale trauma/extremities/oth orthoped
implant total sale medsurg total sale neurotechnology/spin
sale next two year view one best posit compani
large-cap univers sustain upper-ti organ sales/ebitda/ep growth drive
sharehold return given new product cycl across divis help support
division sale growth rate key end-market grow exposure/market
reprocess robot on-going cost/expens optim effort expect
help yield least underli annual ebita margin expans
contribut physio-control acquisit cash market
secur total debt expect use enhanc sharehold valu
continu re-deploy toward share buyback dividend longer-
term potenti gener signific sale synergi forecast out-year estim
mako rio platform spine extrem investor increasingli focu sale
growth factor oper leverag opportun beyond believ stock
move higher consid attract entri point
current share trade cash ep premium large-cap
med-tech averag ew
reflect compani averag sale growth prospect confid syk
average sale growth sustain profit earn growth prospect
capabl track least line larg cap med-tech peer group averag faster
given potenti revenu upsid year potenti invest erp
transatlant cost initi yield meaning oper leverag futur
potenti room accret stepped-up buy-back activ drive upsid estim
given stabil compani top line new product way think
sustain premium vs peer group averag vs appli current
forward multipl ep yield pt
risk valuat includ prolong pullback possibl deterior hospit
purchas trend either due economi uncertainti around limit upsid
potenti medsurg estim unabl gain hundr basi point market
share result total knee launch mako system -- -or adapt mako system new
ortho indic deploy cash possibl dilut acquisit new
product launch robot success forecast gener
increas sale momentum beyond unabl deliv oper
leverag and/or dd ep growth despit sustain above-averag top-lin growth rate
compani report streetaccount consensu leerink partner llc research
note -- valu base account chang
stryker annual outlook
million except ep
margin sale
compani report leerink partner llc research
sale ex-fx
favor impact fx
unfavor impact
favor impact fx rate
least inprov
least inprov
includ fx new tax act impact
acquisition-rel entellu expect
close dilut full-
favor
favor
impact fx
impact fx
favor impact
fx
compani report leerink partner llc research
exclud impact adopt new revenu recognit standard
dollar million except per share
net sale report
net sale adj
sale
earn incom tax ex-amort
earn incom tax
sale report
sale adj
earn incom tax
compani report leerink partner estim
note adopt effect report number adjust account chang purpos model compar alter quarterli annual revenu sale growth number reflect chang
impact remov sg expens revenu per quarter full year net sale report line item reflect figur report regulatori file
compani report leerink partner llc research
dollar million
revenu million
total sale report
total sale adj
total sale adj
compani report leerink partner estim
note adopt effect report number adjust account chang purpos model compar alter quarterli annual revenu sale growth number reflect chang impact
remov sg expens revenu per quarter full year
compani report leerink partner llc research
